By Kate Kelland LONDON (Reuters) - GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa. The British drugmaker said the shot, called RTS,S, is intended exclusively for use outside the European Union but will be evaluated by the European Medicines Agency (EMA) in collaboration with the World Health Organisation (WHO). Malaria, a mosquito-borne parasitic disease, kills more than 600,000 people a year, mainly babies in the poorest parts of sub-Saharan Africa. Yet hopes that RTS,S would be the final answer to wiping out malaria were dampened when results from a final-stage trial in babies aged six to 12 weeks showed the shot provided only modest protection, reducing episodes of the disease by 30 percent compared to immunization with a control vaccine.
The European Central Bank has received a blackmail letter after its public website was hacked and contact data stolen, the bank said on Thursday. "There has been a breach of the security protecting a database serving (our) public website," the ECB said in a statement. "The database serves parts of the ECB website that gather registrations for events such as ECB conferences and visits. It is physically separate from any internal ECB systems," the statement said.